Palantir Issues Additional Details About Life Sciences Capabilities to be Shown at “Double Click” on Wednesday, April 14,...
April 01 2021 - 6:59AM
Business Wire
Palantir Technologies (NYSE:PLTR) today issued additional
details about the Palantir Foundry capabilities it will be
highlighting in its Life Sciences demo at “Double Click” on
Wednesday, April 14, 2021, at 11:00am ET.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210401005274/en/
Palantir’s customers in Life Sciences span pharmaceuticals,
research institutions, healthcare systems, and others. These
customers rely on Foundry’s secure and collaborative architecture
to discover and develop drugs, manage commercial launches, conduct
clinical research, and distribute vaccines. For example:
- More than 1,000 researchers at the NIH’s National COVID Cohort
Collaborative (N3C) use Foundry to securely maintain one of the
largest patient-level data assets of COVID-19 Electronic Health
Record (EHR) data in the world and collaborate on more than 150
research projects (as illustrated in this video demonstration by
N3C).
- Thousands of General Practitioners at NHS England order,
allocate, track, and deliver every one of the 29+ million vaccines
administered in the country to date (as outlined in the UK
Government's website for data and insights on COVID-19).
At the first installment of Palantir’s Double Click series,
engineers will demo the latest Foundry capabilities, as well as
several new Archetypes available on top of Foundry that make this
work possible in a matter of clicks, including:
- Reproducible research in any environment. Foundry’s
interoperable, modular, and open architecture enables users of
varying technical ability to integrate any data, use any tool,
manage any model, and write code in any language — while
maintaining end-to-end reproducibility, transparency, and security
of their analyses. Foundry integrates its governance and knowledge
management capabilities with common data science environments such
as RStudio or HPC clusters, enabling users to work reproducibly
with any libraries of their choice — from specialized
bioinformatics tools such as plink to machine learning libraries
such as scikit-learn, tensorflow, or MLlib.
- Purpose-based access controls. Foundry’s Purpose-Based
Access Controls Archetype enables automated or managed assignment
of permissions based on the proposed use of a particular data
source or dataset. By systematically encoding data access requests
alongside the context of the associated research, these access
controls provide governance administrators with granular insight
into every analysis a piece of data is used for, by whom, and for
what reason.
- Systematic model management. Foundry’s Model Management
Archetype supports the governance and deployment of predictive
models, including those developed outside Foundry. Researchers can
readily reproduce results, track how each version of a model was
developed, automatically update models when upstream source data
changes, compare performance metrics, and tag versions for release
into staging or production environments. Models can be deployed
within Foundry (batch or streaming, or API endpoint for ad-hoc
querying) or to external systems, including specialized hardware.
Health checks, telemetry, and rich model monitoring of deployments
help organizations go beyond model drift to understand and manage
their models against real-world scenarios.
- Out of the box pipeline templates for standardized data
models. Foundry’s Pipeline Archetype deploys pre-built data
pipelines that convert common real-world data sources such as Optum
claims or TriNetX into standard data models, such as OMOP. This
enables researchers to easily pivot between sources, and reuse
cohort code lists or analytic methods that have already been
defined by the open-source community. For unique data sources, such
as historic Randomized Controlled Trials, Foundry’s machine
learning-powered Entity Resolution Archetype provides the framework
for automatically suggesting mappings to a user-defined data model
and enabling human-driven confirmation.
For examples of research studies and publications powered by
Palantir Foundry, please see the list below.
About Palantir Double Click
Palantir software is used by customers across 40 industries
worldwide. Double Click is Palantir's series of software demo
events that showcase how the company's platforms are used across
these industries and customers.
Advance registration is required, and is available at
https://palantir.events/doubleclick. Capacity is limited, and
registration will close 24 hours prior to the event. For more
information regarding the event, please visit
https://www.palantir.com/double-click or email
double-click@palantir.com.
About Palantir Technologies Inc.
Palantir Technologies Inc. builds and deploys operating systems
for the modern enterprise. Additional information is available at
https://www.palantir.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements may relate to, but are not limited to,
Palantir’s expectations regarding the event and the expected
performance and benefits of, or anticipated updates to, its
software platforms. Forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be
predicted or quantified. Forward-looking statements are based on
information available at the time those statements are made and
were based on current expectations as well as the beliefs and
assumptions of management as of that time with respect to future
events. These statements are subject to risks and uncertainties,
many of which involve factors or circumstances that are beyond our
control. These risks and uncertainties include, but are not limited
to, our ability to meet the unique or anticipated needs of our
customers; the failure of our platforms to satisfy our customers or
perform as desired; the frequency or severity of any software and
implementation errors; and our platforms’ reliability. Additional
information regarding these and other risks and uncertainties is
included in the filings we make with the Securities and Exchange
Commission from time to time. Except as required by law, we do not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments, or otherwise.
Third-Party Websites and References
This press release contains links to third party websites or
information, which are provided for informational purposes only and
are not incorporated by reference herein. You are solely
responsible for your own assessment of such information and we make
no representations as to their accuracy or completeness nor do we
undertake to verify or update any such information. The inclusion
of third party links does not constitute endorsement by us of the
linked websites or any information or other linked information
contained therein.
All third-party products, publications, and names referenced
herein are the property of their respective owners. Use of such
references is for identification purposes only and does not imply
any affiliation with or endorsement by such third-parties.
Select Publications Powered by Palantir Foundry
- Shallcross et al., 2021. Factors associated with SARS-CoV-2
infection and outbreaks in long-term care facilities in England: a
national cross-sectional survey. The Lancet Healthy Longevity.
- Dorjsuren et al., 2021. Chemoprotective antimalarials
identified through quantitative high-throughput screening of
Plasmodium blood and liver stage parasites. Scientific
Reports.
- Haendel et al., 2020. The National COVID Cohort Collaborative
(N3C): Rationale, design, infrastructure, and deployment.
JAMIA.
- Vellanki et al., 2020. Evaluation of the correlation between
antibiotic use and survival in patients with recurrent or
metastatic head and neck squamous cell carcinoma (R/M HNSCC)
treated with immune checkpoint inhibitors (ICIs). ASCO 2020.
- Weinstock et al., 2020. Impact of timing of antibiotic use on
clinical outcomes in patients with urothelial cancer treated with
immune checkpoint inhibitors (ICIs). ASCO 2020.
- Gao et al., 2019. CDK4/6 inhibitor treatment for patients with
hormone receptor-positive, HER2-negative, advanced or metastatic
breast cancer: a US Food and Drug Administration pooled analysis.
The Lancet Oncology.
- Mitchell et al., 2019. Recurrent PTPRT/JAK2 mutations in lung
adenocarcinoma in African Americans. Nature Communications.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210401005274/en/
Lisa Gordon media@palantir.com
Palantir Technologies (NYSE:PLTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Palantir Technologies (NYSE:PLTR)
Historical Stock Chart
From Apr 2023 to Apr 2024